Rationale: The orphan nuclear receptor NOR1 is a member of the evolutionary highly conserved and ligandindependent NR4A subfamily of the nuclear hormone receptor superfamily. Members of this subfamily have been characterized as early response genes regulating essential biological processes including inflammation and proliferation; however, the role of NOR1 in atherosclerosis remains unknown. Objective: The goal of the present study was to determine the causal contribution of NOR1 to atherosclerosis development and to identify the mechanism by which this nuclear receptor participates in the disease process.
T he transcription factor NOR1 (NR4A3) belongs to the highly conserved NR4A subfamily of orphan nuclear hormone receptors. 1, 2 Members of this subgroup are classified as early response genes, which are induced by a pleiotropy of stimuli, including mitogens and inflammatory signals. 3, 4 In contrast to other members of the nuclear receptor superfamily, NR4A receptors function as constitutively active and ligand-independent transcription factors. 5, 6 Therefore, the transcriptional activity of NR4A receptors is determined by the expression level and by posttranslational modifications of the receptor. 7 NR4A receptors positively regulate target gene expression by binding as monomer or homodimer to different variations of the canonical 5Ј-A/TAAAGGTCA NGFI-B response element (NBRE). 8 In addition, Nur77 (NR4A1) and Nurr1 (NR4A2) exhibit transcriptionally distinct mechanisms, because both are able to transactivate target genes as a heterodimer with RXR. 9 Consistent with the pleiotropic stimuli that induce the expression of NR4A receptors, these transcription factors have been implicated in regulating key cellular functions, including inflammation, proliferation, and cell survival. 1, 2 NOR1 was first cloned from neuronal cells, and its deletion in mice results in hippocampal dysgenesis and inner ear defects. 10, 11 In addition to neurons, NOR1 is highly expressed in atherosclerotic lesions. 3, [12] [13] [14] NOR1 is induced by mitogens in smooth muscle cells and required for proliferative remodeling following vascular injury. 3, 14, 15 In macrophages, NOR1 is induced during inflammation and represses cytokine secretion. 4, 13 Finally, NOR1 expression is increased by vascular endothelial growth factor in endothelial cells. 16 However, the functional role of NOR1 in endothelial cells and its contribution to atherosclerosis remain to be investigated.
In the present study, we provide first evidence that NOR1 plays an essential role in the regulation of monocyte adhesion to the endothelium by positively regulating vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 expression. In vivo, loss of NOR1 function in apolipoprotein (apo)E-deficient mice reduces atherosclerosis formation and macrophage recruitment to the arterial wall. These studies identify NOR1 as a previously unrecognized key component of a transcriptional cascade regulating monocyte adhesion during atherogenesis.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice
Littermate NOR1 Ϫ/Ϫ and NOR1 ϩ/ϩ mice on a mixed C57BL/6J/ 129Sv background were used as previously described. 14, 15 ApoE Ϫ/Ϫ mice on a C57BL/6J background (N10) were obtained from The Jackson Laboratory (stock no. 002052) and interbred with NOR1 Ϫ/Ϫ mice to obtain NOR1 Ϫ/Ϫ apoE Ϫ/Ϫ mice. At 8 to 10 weeks of age, littermate female NOR1 ϩ/ϩ apoE Ϫ/Ϫ , NOR1 ϩ/Ϫ apoE Ϫ/Ϫ , and NOR1 Ϫ/Ϫ apoE Ϫ/Ϫ mice were fed a saturated fat enriched diet (TD88137; Harlan Teklad) for 12 weeks for atherosclerosis analysis or for 2 weeks to analyze NR4A gene expression.
Isolation of Murine Endothelial Cells
Mouse aortic endothelial cells (MAECS) were isolated from aortae of littermate NOR1 ϩ/ϩ and NOR Ϫ/Ϫ mice using an explant technique. Aortic segments were placed on Cultrex Basement Membrane Extract gel (R&D Systems) and incubated in low-glucose DMEM supplemented with 15% FBS, 180 g/mL heparin, and 20 g/mL endothelial cell growth supplement. Migrated endothelial cells were passaged using dispase (BD Sciences) and cultured for 2 days in media containing D-valine to limit fibroblast contamination. Once confluent, MAECS were incubated with tumor necrosis factor (TNF)␣ (R&D Systems) as indicated.
Adhesion Assay
Human umbilical cord vein cells (HUVECs) were infected with 50 plaque-forming unit (pfu) Ad-CMV-null or Ad-CMV-NOR1 for 6 hours and recovered for 48 hours. HUVECs treated with TNF␣ were used as a positive control. THP-1 monocytes were prestained with 5 mol/L calcein-AM (Sigma-Aldrich) at 37°C for 30 minutes. After washing in PBS, fluorescently labeled THP-1 monocytes were added onto the HUVEC monolayers at the density of 10 6 cells/mL. To block VCAM-1 and ICAM-1 function, HUVEC monolayers were incubated with blocking antibodies against VCAM-1 (25 g/mL, BBA5, R&D Systems) and ICAM-1 (10 g/mL, BBA3, R&D Systems) for 1 hour before the addition of THP-1 monocytes. Nonadherent monocytes were washed off after 30 minutes. For mouse monocyte adhesion assays, the thoracic aortae of littermate NOR1 ϩ/ϩ or NOR1 Ϫ/Ϫ mice were cut into segments, pinned on dental wax, and maintained in MAEC growth media supplemented with TNF␣ (1 ng/mL) or vehicle (PBS). After 6 hours, aortae were washed with PBS, and 700 L of fluorescently labeled WEHI-274.1 cells were added at the density of 10 6 cells/mL. Nonadherent monocytes were removed after 30 minutes by washing with PBS. For both experiments, 6 pictures were taken for each condition, and adhesion was quantified by counting fluorescent monocytes attached to the endothelium.
Results

NOR1 Is Expressed in Endothelial Cells of Human Coronary Atherosclerotic Lesions
To characterize the distribution of NOR1 expression in atherosclerosis, human coronary arteries were immunostained for NOR1. NOR1 protein was readily detectable in atherosclerotic lesions ( Figure 1A ) but negligible in normal arteries (data not shown). In these atherosclerotic sections, high levels of NOR1 immunostaining were observed in the endothelial cell layer and in subendothelial cells of advanced atherosclerotic lesions. Colocalization experiments using confocal microscopy confirmed a typical nuclear expression pattern of NOR1 in endothelial cells staining positive for the endothelial cell marker von Willebrand factor ( Figure 1B ).
NOR1 Is Induced by Inflammatory Stimuli in Endothelial Cells
In vitro, stimulation of HUVECs with the inflammatory mediators interleukin-1␤, oxidized low-density lipoprotein, lipopolysaccharide, or TNF␣ highly induced NOR1 mRNA expression ( Figure 2A ). In contrast, interleukin-6 or interferon-␥ did not significantly induce NOR1 transcript levels in HUVECs. Considering that TNF␣ elicited a maximal increase in NOR1 expression, subsequent experiments focused on the regulation of NOR1 by TNF␣. Consistent with previous reports characterizing NOR1 as an early response gene, 3, 4 time course experiments confirmed a maximal induction of NOR1 mRNA after 3 hours of TNF␣ stimulation ( Figure 2B ). This increase in NOR1 transcript levels was followed by a maximal induction of NOR1 protein expression Figure 2C and 2D). The observed regulation of NOR1 mRNA and protein expression by TNF␣ was dosedependent, revealing a maximal increase of NOR1 expression with 1 ng/mL TNF␣ ( Figure 2E through 2G, respectively). Finally, TNF␣ induced a similar induction of NOR1 mRNA expression in primary MAECS isolated from NOR1 wildtype mice (Online Figure I) . In contrast, the other 2 members of the NR4A subfamily, Nur77 and Nurr1, were only modestly induced in NOR1 wild-type cells, and this induction was lost in NOR1 Ϫ/Ϫ MAECS.
NOR1 Expression in Endothelial Cells Is Mediated Through an Nuclear Factor B-Dependent Transactivation of the NOR1 Promoter
NOR1 is primarily regulated through transcriptional mechanisms, and sequence analysis of the NOR1 promoter identified several putative nuclear factor (NF)-B binding sites. To address the functional relevance of these NF-B sites, endothelial cells were infected with an adenoviral construct overexpressing a dominant-negative IB␣ mutant. In cells overexpressing green fluorescent protein (GFP) as control, TNF␣ treatment resulted in a significant increase of NOR1 mRNA expression ( Figure 3A ). In contrast, overexpression of the dominant-negative IB␣ mutant resulted in an almost complete inhibition of TNF␣-induced NOR1 mRNA expression. These experiments indicate that TNF␣-induced NOR1 expression is primarily mediated via NF-B signaling in endothelial cells.
To further confirm an NF-B-dependent transcriptional regulation of NOR1 expression in endothelial cells, we performed transient transfection assays using a NOR1 promoter construct. This 4.0-kb full-length human NOR1 pro-moter construct includes 2 putative NF-B-binding sites at Ϫ595 to Ϫ586 and Ϫ198 to Ϫ190 from the transcription initiation site ( Figure 3B ). Stimulation of endothelial cells with TNF␣ resulted in a significant activation of the fulllength NOR1 promoter ( Figure 3C ). This induction of the NOR1 promoter was maintained on 5Ј deletion to 1.7 kb but completely abolished following mutation of the 2 NF-Bbinding sites, confirming that TNF␣ induces NOR1 promoter activity via an NF-B-dependent transactivation of the promoter. As depicted in Figure 3D and 3E, chromatin immunoprecipitation (ChIP) assays revealed the recruitment of p65 to the NF-B site in the endogenous NOR1 promoter in response to TNF␣. Maximal promoter occupancy was observed after 3 hours, which is consistent with the kinetics of NOR1 mRNA expression in response to inflammatory stimuli. In concert, these data demonstrate that TNF␣ induces NOR1 expression through a NF-B-dependent signaling pathway, resulting in the subsequent transactivation of the proximal NOR1 promoter.
NOR1 Positively Regulates VCAM-1 and ICAM-1 in Endothelial Cells
To explore whether NOR1 is involved in the transcriptional control of endothelial cell responses, we next infected HUVECs with an adenovirus overexpressing human NOR1 ( Figure 4A ). As depicted in Figure 4B through 4E, NOR1 overexpression resulted in a prominent induction of VCAM-1 and ICAM-1 mRNA and protein expression levels, respectively.
We next used a murine model to address whether NOR1 is also required for VCAM-1 and ICAM-1 expression in endothelial cells. In these experiments, MAECS were isolated from littermate NOR1 wild-type and NOR1-deficient mice. 14, 15 As depicted in Figure 5A through 5E, TNF␣ stimulation profoundly increased VCAM-1 and ICAM-1 mRNA and protein expression in NOR1 wild-type MAECS. In contrast, the induction of both adhesion molecules was markedly reduced in MAECS isolated from NOR1-deficient mice. Similar data were obtained when cells were stimulated with interleukin-1␤ or lipopolysaccharide (Online Figure II , A through C).
NOR1 Transactivates the VCAM-1 Promoter by Binding to a Canonical NBRE Consensus Site
We next performed transient transfection assays to investigate the underlying mechanism by which NOR1 regulates VCAM-1 expression in endothelial cells. NOR1 induces transcription by binding to NBRE consensus sites in target gene promoters. 8 Interestingly, sequence analysis of the human VCAM-1 promoter identified a canonical NBRE site at Ϫ2618 bp from the transcription initiation site ( Figure 6A ). Transient transfection of HUVECs with a luciferase reporter construct driven by the human 3.0-kb VCAM-1 promoter revealed that overexpression of NOR1 increases VCAM-1 promoter activity ( Figure 6B ). However, this transcriptional induction was significantly altered on site-directed mutagenesis of the canonical NBRE motif. ChIP assays subsequently confirmed that TNF␣ induced the recruitment of NOR1 to this NBRE site in the VCAM-1 promoter ( Figure 6C) . These experiments demonstrate that NOR1 transactivates the VCAM-1 promoter by binding to a NBRE consensus site in the promoter and characterize VCAM-1 as NOR1-regulated target gene.
NOR1 Mediates Monocyte Adhesion by Regulating VCAM-1 and ICAM-1 Expression
VCAM-1 and ICAM-1 have both been well characterized to mediate monocyte adhesion to the endothelium, leading to the infiltration of monocytes into the subendothelial area and atherosclerosis development. 17 To investigate whether the transcriptional induction of VCAM-1 and ICAM-1 by NOR1 is sufficient to promote monocyte adhesion, we analyzed THP-1 monocyte adhesion to HUVECs overexpressing NOR1. Stimulation of a HUVEC monolayer with TNF␣ profoundly increased monocyte adhesion, confirming the validity of the assay (Figure 7A, top) . Compared to HUVECs infected with an adenovirus overexpressing an empty vector as control, overexpression of NOR1 significantly increased monocyte adhesion in the absence of TNF␣ stimulation ( Figure 7A and 7B ). Furthermore, monocyte adhesion induced by NOR1 overexpression was almost completely abolished by preincubation of HUVECs with VCAM-1 and ICAM-1 blocking antibodies ( Figure 7A and 7B). Conversely, acute knockdown of NOR1 in HUVECs using small interfering RNA significantly decreased monocyte adhesion (Online Figure III, A through C) . Collectively, these studies indicate that NOR1 is necessary and sufficient for monocyte adhesion and that this activity is mediated primarily by inducing the expression of VCAM-1 and ICAM-1. To further confirm a causal contribution of NOR1dependent VCAM-1 and ICAM-1 expression for monocyte adhesion ex vivo, we performed adhesion assays with aortae isolated from NOR1 ϩ/ϩ and NOR1 Ϫ/Ϫ mice. Incubation with TNF␣ significantly increased the adhesion of monocytes to the aortic endothelial cell layer of NOR1 wild-type mice ( Figure 7C and 7D ). However, this inducible adhesion was completely abolished on aortae of NOR1-deficient mice. From these findings we infer that NOR1 expression in resident endothelial cells is necessary for mediating monocyte adhesion.
NOR1 Deficiency Decreases Atherosclerosis Formation and Reduces Macrophage Recruitment in ApoE ؊/؊ Mice
Considering that monocyte adhesion constitutes a critical initial step for atherogenesis, 17 Figure  8A and 8B). NOR1 deficiency revealed no overt effect on cholesterol distribution confirming a direct effect of NOR1 on lesion formation ( Figure 8C ). Immunostaining of atherosclerotic tissues and quantification of the macrophage content confirmed macrophage-enriched lesions in NOR1 ϩ/ϩ apoE Ϫ/Ϫ mice that were considerably less with decreased macrophage content in NOR1 Ϫ/Ϫ apoE Ϫ/Ϫ mice ( Figure 8D and 8E; Online Figure IV) . Finally, whereas VCAM-1 was readily detectable in atherosclerotic lesions from NOR1 ϩ/ϩ apoE Ϫ/Ϫ mice, there was a paucity of immunoreactivity for this adhesion molecule noted in the vascular wall of NOR1 Ϫ/Ϫ apoE Ϫ/Ϫ mice ( Figure 8F ).
Discussion
Monocyte adhesion constitutes a critical event for the initiation of atherosclerosis 17 ; however, the molecular mechanisms that orchestrate monocyte-endothelial cell interactions are incompletely understood. In the present study, we report a previously unrecognized role for the nuclear receptor NOR1 to serve as a transcriptional regulator of adhesion molecule expression and monocyte recruitment during atherosclerosis. In endothelial cells, NOR1 is rapidly induced by inflammatory stimuli via an NF-Bdependent transactivation of the NOR1 promoter. Loss-and gain-of-function studies establish that NOR1 positively regulates VCAM-1 and ICAM-1 expression in endothelial cells, leading to increased monocyte adhesion. Consistent with the key role of NOR1 to promote monocyte adhesion to the endothelium, our studies further demonstrate that NOR1 deficiency results in decreased atherosclerosis development and macrophage recruitment in apoE-deficient mice.
Consistent with recent studies, we identified abundant NOR1 expression in endothelial cells, 12 as well as in cells of the subendothelial space likely representing macrophages and smooth muscle cells. 4, 13, 14, 18 However, the transcriptional mechanisms governing inducible NOR1 expression in endothelial cells remain elusive. Our data provide evidence for an NF-Bdependent induction of NOR1 transcription during endothelial cell inflammation. Inhibition of NF-B signaling in endothelial cells repressed inducible NOR1 expression in response to inflammatory stimulation. Using site-directed mutagenesis and ChIP assays, we identified 2 functional NF-B sites in the NOR1 promoter, to which p65 is recruited during inflammatory activation of endothelial cells. Earlier studies have demonstrated that NOR1 expression in endothelial cells is highly induced by mitogens through a CREB (cAMP response element binding protein)-dependent activation of the proximal region of NOR1 promoter. 16 Furthermore, hypoxia has recently been reported to induce NOR1 in endothelial cells through a mechanism involving the hypox- ia-inducible factor family of transcription factors. 19 These studies, in concert with our data characterizing NOR1 as a NF-B target gene in endothelial cells, point to distinct transcriptional mechanisms regulating the rapid NOR1 induction in response to various environmental cues.
Compared with the well-studied early-response genes encoding proteins of the activator protein-1 complex, little is known about the physiological function of NOR1 and its regulated target genes, yet the high degree of conservation points to an important role in the control of gene expression. A previous study has provided initial evidence to support a functional role of NOR1 in endothelial cells by demonstrating that NOR1 regulates growth of this cell type. 16 The data presented here extend these findings and points to an unsuspected function of NOR1 to serve as a positive regulator of monocyte adhesion. In experiments using adenoviralmediated overexpression, NOR1 induced VCAM-1 and ICAM-1 expression, resulting in increased monocyte adhesion. The observation that this inducible adhesion was abolished when VCAM-1 and ICAM-1 function were blocked suggests that the induction of both adhesion molecules by NOR1 constitutes a primary mechanism by which NOR1 induces monocyte adhesion. Conversely, the inducible expression of both adhesion molecules in response to inflammatory activation was attenuated in NOR1-deficient endothelial cells. Furthermore, consistent with these findings, TNF␣induced monocyte adhesion to HUVECs transfected with NOR1 small interfering RNA or to the endothelium of NOR-deficient mice was altered ex vivo, suggesting that vascular NOR1 expression is not only sufficient but also required for monocyte adhesion.
An intriguing question that arises from the observation that NOR1 induces the expression of VCAM-1 and ICAM-1 relates to the mechanisms by which NOR1 positively regulates these genes. Initial sequence analysis identified putative NBRE consensus sites in both the VCAM-1 and ICAM-1 promoters. Exemplified by the VCAM-1 promoter, our studies demonstrate that the molecular mechanisms underlying this novel function of NOR1 involve, at least in part, a direct transactivation of the VCAM-1 promoter by NOR1. In response to inflammatory activation NOR1 is recruited to a canonical NBRE site in the VCAM-1 promoter. Moreover, the observation that NOR1-dependent VCAM-1 promoter transactivation was attenuated on mutation of this NBRE site confirms the functionality of this NBRE motif. However, the residual induction of the VCAM-1 promoter bearing a mutation of this NBRE site suggests that additional transcriptional mechanisms may regulate NOR1 expression. NOR1 has recently been shown to transactivate the inducible IB kinase (IKKi/IKK⑀) promoter, which phosphorylates IB␣ and induces NF-B activation. 20 Therefore, in addition to a direct transactivation, NOR1 may function as a positive upstream regulator of NF-B signaling and indirectly activate the VCAM-1 and ICAM-1 promoters. Alternatively, NOR1 deficiency may affect other transcriptional networks acting on these promoters, including for example the activator protein-1 complex. We have recently demonstrated that the combined deficiency of NOR1 and its sibling Nur77 decreases the expression of activator protein-1 transcription factors, 21 which may regulate adhesion molecule expression. 22 Clearly, the findings presented here provide justification for further investigating the transcriptional mechanisms by which NOR1 regulates endothelial cell gene expression and promotes monocyte adhesion.
The protein products of the VCAM-1 and ICAM-1 genes are well established to participate in atherogenesis by promoting macrophage accumulation in the arterial intima. 17 Consistent with this evidence and with the observed regulation of endothelial cell adhesion molecule expression by NOR1, we provide the first evidence that NOR1 deficiency decreases atherosclerosis in apoE-deficient mice. Considering that all 3 members of the NR4A receptor subfamily bind to an NBRE site, functional redundancy in certain cell types between Nur77 and NOR1 has been suggested. 23 However, NOR1 deficiency did not result in a compensatory upregulation of the siblings Nur77 and Nurr1 in endothelial cells (Online Figure I) or in the aortae of NOR1 Ϫ/Ϫ apoE Ϫ/Ϫ mice (Online Figure V) . Therefore, the previously reported phenotypes in NOR1-deficient mice, 10, 11, 15 in concert with the decreased atherosclerosis in NOR1 Ϫ/Ϫ apoE Ϫ/Ϫ mice presented in this study, point to a function of NOR1 that is distinct and not compensated by Nur77 or Nurr1. As evidenced by the decreased accumulation of macrophages in the vascular wall of NOR1 Ϫ/Ϫ apoE Ϫ/Ϫ mice, monocyte recruitment represents at least one plausible mechanism by which NOR1 acts atherogenic. However, it is possible, if not likely, that there are additional mechanisms by which NOR1 promotes atherosclerosis development. NOR1 induces neointimal proliferation of SMC 15 and inflammatory gene expression in macrophages, 20 which both could affect lesion development. Therefore, characterization of the cell-specific role of NOR1 in atherosclerosis will be necessary and will have to rely on tissue-specific gene targeting strategies. In conclusion, data presented here characterize the orphan nuclear receptor NOR1 as a novel positive regulator of monocyte adhesion by inducing VCAM-1 and ICAM-1 transcription. Continued investigation of the transcriptional networks regulated by NOR1 will provide new insights into how this orphan nuclear receptor participates in the development of vascular diseases.
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